Abstract
Two patients with high-risk acute myeloid leukemia (AML) whose bone marrow aspirates showed more than 25% blasts between 2 and 4 weeks after the first induction chemotherapy immediately received modified conditioning therapy with intravenous busulfan at 50% of the usual dose and fludarabine, before hematologic recovery occurred. Unmanipulated G-CSF mobilized peripheral blood stem cells from an HLA-identical sibling donor were transfused and haematopoietic recovery was achieved in both recipients. Both of them are in continuing hematological remission with full donor chimerism 12 and 22 months after transplantation. Early treatment intensification with allogeneic cell therapy during marrow aplasia might cure high-risk AML patients who are unlikely to achieve remission with conventional chemotherapy protocols. Bone Marrow Transplantation (2001) 27, 543–546.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others
References
Keating MJ, Smith TL, Gehan EA et al. Factors related to length of complete remission in adult acute leukemia Cancer 1980 45: 2017–2029
Berman E, Little C, Gee T et al. Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation New Engl J Med 1992 326: 156–160
Estey E, Shen Y, Thall PF . Effect of time to complete remission on subsequent survival and disease-free survival time in AML, RAEB-t, and RAEB Blood 2000 95: 72–77
Grigg AP, Szer J, Beresford J et al. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukemia Br J Haematol 1999 107: 409–418
Thiede C, Florek M, Bornhäuser M et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection Bone Marrow Transplant 1999 23: 1055–1060
Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia J Clin Oncol 1992 10: 1723–1729
Byrne JL, Dasgupta E, Pallis M et al. Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG Leukemia 1999 13: 786–791
Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756–763
McSweeney PA, Wagner JL, Maloney DG et al. Outpatient PBSC allografts using immunosuppression with low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant Blood 1998 92: (Suppl. 1) 519a
Xun CQ, McSweeney PA, Boeckh M et al. Successful nonmyeloablative allogeneic hematopoietic stem cell transplant in an acute leukemia patient with chemotherapy-induced marrow aplasia and progressive pulmonary aspergillosis Blood 1999 94: 3273–3276
Bornhäuser M, Thiede C, Schuler U et al. Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin Bone Marrow Transplant 2000 26: 119–125
Harousseau JL, Cahn JY, Pignon B et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM) Blood 1997 90: 2978–2986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Platzbecker, U., Thiede, C., Freiberg-Richter, J. et al. Early allogeneic blood stem cell transplantation after modified conditioning therapy during marrow aplasia: stable remission in high-risk acute myeloid leukemia. Bone Marrow Transplant 27, 543–546 (2001). https://doi.org/10.1038/sj.bmt.1702819
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bmt.1702819
Keywords
This article is cited by
-
Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial
Leukemia (2015)
-
Biologie und risikoadaptierte Therapie der akuten myeloischen Leukämie
Onkopipeline (2009)
-
Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up
Bone Marrow Transplantation (2006)
-
Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia
Leukemia (2006)
-
Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial
Leukemia (2003)